Tobam boosted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 57.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 226,938 shares of the company’s stock after buying an additional 83,080 shares during the period. Johnson & Johnson makes up 2.3% of Tobam’s investment portfolio, making the stock its 14th biggest holding. Tobam’s holdings in Johnson & Johnson were worth $35,175,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of JNJ. GW&K Investment Management LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at about $35,000. Dark Forest Capital Management LP increased its position in shares of Johnson & Johnson by 1,044.4% during the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after buying an additional 188 shares during the period. Ruedi Wealth Management Inc. bought a new stake in Johnson & Johnson during the fourth quarter worth about $42,000. Kepos Capital LP bought a new stake in Johnson & Johnson during the fourth quarter worth about $45,000. Finally, VitalStone Financial LLC bought a new stake in Johnson & Johnson during the fourth quarter worth about $52,000. 67.57% of the stock is owned by institutional investors.
Insider Buying and Selling
In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock worth $7,928,856 in the last 90 days. 0.20% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
View Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Price Performance
Johnson & Johnson stock opened at $169.91 on Thursday. The stock has a market cap of $441.55 billion, a price-to-earnings ratio of 34.39, a price-to-earnings-growth ratio of 2.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The firm has a 50-day moving average of $162.48 and a two-hundred day moving average of $161.10.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. The business had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. During the same quarter in the previous year, the business posted $2.59 EPS. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 10.76 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be paid a dividend of $1.19 per share. The ex-dividend date is Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.80%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 5 Best Office REITs to Buy Now
- Why Average Daily Trading Volume Matters to Every Investor
- Camping World Slashes its Dividend but Should You Cut the Stock?
- How to Build Wealth with the Dividend Aristocrat Index
- SoFi Downgraded: Here’s How To Still Make Money
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
